Get the Stockscreener App
28.82
1.20%
-0.35
Damora Therapeutics Inc stock is traded at $28.82, with a volume of 564.86K.
It is down -1.20% in the last 24 hours and up +31.00% over the past month.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
See More
Previous Close:
$29.17
Open:
$29.79
24h Volume:
564.86K
Relative Volume:
1.03
Market Cap:
$1.77B
Revenue:
-
Net Income/Loss:
$-209.84M
P/E Ratio:
-6.3063
EPS:
-4.57
Net Cash Flow:
$-6.73M
1W Performance:
-8.45%
1M Performance:
+31.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$28.48
$30.00
1-Week Range:
$28.25
$34.89
52-Week Range:
$16.50
$34.89
Damora Therapeutics Inc Stock (DMRA) Company Profile
Name
Damora Therapeutics Inc
Sector
Industry
Phone
(781) 281-9020
Address
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
28.82 | 1.77B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-25-26 | Initiated | Evercore ISI | Outperform |
| Feb-17-26 | Initiated | UBS | Buy |
| Jan-07-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Guggenheim | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
View All
Damora Therapeutics Inc Stock (DMRA) Latest News
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Damora Therapeutics (DMRA) AGM 2026 Summary - Quartr
Damora Therapeutics (DMRA) Proxy filing Summary - Quartr
symbol__ Stock Quote Price and Forecast - CNN
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
DMRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
H.C. Wainwright reiterates Buy on Damora Therapeutics stock By Investing.com - Investing.com Canada
Damora Therapeutics Completes Cayman Islands Redomestication - TipRanks
Damora Therapeutics completes redomestication to Cayman Islands - Investing.com
Damora Announces Redomestication from Delaware to Cayman Islands - The Manila Times
Damora Will Keep DMRA Ticker Under New Nasdaq CUSIP July 20 - Stock Titan
Damora Therapeutics Completes Redomestication to Cayman Islands (DMRA) - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Damora Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerGeographic Revenue Trends - dars.gov.et
Is Broad Russell Index Inclusion Altering The Investment Case For Damora Therapeutics (DMRA)? - simplywall.st
Damora Therapeutics (DMRA) Sheds Over 6%: Support Levels in Focus After Sharp DeclineDealer Delta - dars.gov.et
Form 4 Damora Therapeutics Inc For: 7 July By Investing.com - Investing.com South Africa
Damora Therapeutics general counsel sells $7,345 in stock By Investing.com - Investing.com Nigeria
Damora Therapeutics general counsel sells $7,345 in stock - Investing.com
[Form 4] Damora Therapeutics, Inc. Insider Trading Activity - Stock Titan
Price to earnings forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Price to sales forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Damora awards 453,500 stock options to nine new hires - Stock Titan
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Index - marketscreener.com
Damora Therapeutics (DMRA) Is Up 6.2% After Broad Russell Index Additions Has The Bull Case Changed? - simplywall.st
Damora Therapeutics, Inc. Actuals & Estimates (NASDAQ:DMRA) - TradingView
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Value Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Damora Therapeutics (DMRA) Slides 4.5%: Key Support Levels in FocusGamma Flip Level - DonanımHaber
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000 Value Benchmark - marketscreener.com
Damora Therapeutics Rises as Traders Focus on Near-Term Pipeline Catalysts - Quiver Quantitative
DMRA Forecast — Price Target — Prediction for 2027 - TradingView
Form 144 Damora Therapeutics For: 22 June By Investing.com - Investing.com India
Damora Therapeutics Inc Stock (DMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):